ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 77 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q2 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $234,048 | -61.2% | 300,061 | -54.0% | 0.00% | – |
| Q2 2023 | $603,065 | +184323.5% | 651,962 | +117.6% | 0.00% | – |
| Q1 2023 | $327 | +36.2% | 299,592 | +81.9% | 0.00% | – |
| Q4 2022 | $240 | -98.0% | 164,659 | +1343.9% | 0.00% | – |
| Q3 2022 | $12,000 | -94.2% | 11,404 | -90.7% | 0.00% | – |
| Q2 2022 | $208,000 | -93.0% | 122,122 | -91.6% | 0.00% | -100.0% |
| Q1 2022 | $2,982,000 | -51.6% | 1,447,614 | -11.9% | 0.00% | -33.3% |
| Q4 2021 | $6,163,000 | -24.8% | 1,643,478 | +3.7% | 0.00% | -40.0% |
| Q3 2021 | $8,194,000 | +106.7% | 1,584,849 | +70.3% | 0.01% | +150.0% |
| Q2 2021 | $3,964,000 | -53.8% | 930,415 | -42.4% | 0.00% | -66.7% |
| Q1 2021 | $8,584,000 | -7.8% | 1,616,533 | -6.4% | 0.01% | -14.3% |
| Q4 2020 | $9,312,000 | +65.6% | 1,727,556 | +145.1% | 0.01% | 0.0% |
| Q3 2020 | $5,624,000 | -68.6% | 704,756 | -60.6% | 0.01% | -72.0% |
| Q2 2020 | $17,894,000 | +351.9% | 1,787,604 | +22.8% | 0.02% | +177.8% |
| Q1 2020 | $3,960,000 | +568.9% | 1,455,879 | +195.2% | 0.01% | +800.0% |
| Q4 2019 | $592,000 | -57.1% | 493,235 | -46.1% | 0.00% | -50.0% |
| Q3 2019 | $1,380,000 | -74.0% | 914,416 | -30.7% | 0.00% | -75.0% |
| Q2 2019 | $5,304,000 | -52.4% | 1,319,292 | -49.0% | 0.01% | -52.9% |
| Q1 2019 | $11,132,000 | -15.8% | 2,588,740 | +12.6% | 0.02% | -19.0% |
| Q4 2018 | $13,215,000 | -65.4% | 2,298,272 | -18.4% | 0.02% | -55.3% |
| Q3 2018 | $38,213,000 | +240.9% | 2,818,048 | +198.4% | 0.05% | +235.7% |
| Q2 2018 | $11,208,000 | -32.5% | 944,255 | -36.1% | 0.01% | -36.4% |
| Q1 2018 | $16,594,000 | +208.4% | 1,477,641 | +83.4% | 0.02% | +214.3% |
| Q4 2017 | $5,381,000 | +11.3% | 805,595 | +36.5% | 0.01% | 0.0% |
| Q3 2017 | $4,833,000 | +334.2% | 590,156 | +138.1% | 0.01% | +250.0% |
| Q2 2017 | $1,113,000 | -71.9% | 247,827 | -65.6% | 0.00% | -71.4% |
| Q1 2017 | $3,967,000 | +45.8% | 720,053 | +7.2% | 0.01% | +16.7% |
| Q4 2016 | $2,720,000 | -40.3% | 671,660 | +3.9% | 0.01% | -25.0% |
| Q3 2016 | $4,558,000 | -17.1% | 646,490 | -4.2% | 0.01% | -38.5% |
| Q2 2016 | $5,500,000 | -26.2% | 674,838 | -26.4% | 0.01% | -31.6% |
| Q1 2016 | $7,452,000 | +79.4% | 916,622 | +166.0% | 0.02% | +111.1% |
| Q4 2015 | $4,155,000 | +84.8% | 344,547 | +83.4% | 0.01% | +125.0% |
| Q3 2015 | $2,248,000 | +4.1% | 187,823 | +59.4% | 0.00% | 0.0% |
| Q2 2015 | $2,160,000 | – | 117,817 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 6,287,101 | $4,903,939 | 2.63% |
| Syncona Portfolio Ltd | 1,377,294 | $1,074,289 | 1.60% |
| MPM BioImpact LLC | 5,095,912 | $3,974,811 | 1.06% |
| NEA Management Company, LLC | 17,079,778 | $13,322,227 | 1.03% |
| TANG CAPITAL MANAGEMENT LLC | 5,166,954 | $4,030,224 | 0.57% |
| PFM Health Sciences, LP | 10,423,135 | $8,130,045 | 0.38% |
| Matrix Capital Management Company, LP | 38,974,185 | $30,399,864 | 0.36% |
| Long Focus Capital Management, LLC | 10,963,158 | $8,551,263 | 0.31% |
| Acuitas Investments, LLC | 479,764 | $374,216 | 0.22% |
| Endurant Capital Management LP | 311,944 | $243,316 | 0.22% |